DxI 9000 Access Immunoassay Analyzer Boasts
Industry’s Highest Throughput per Footprint.
United
States: Beckman Coulter, Inc., a leading diagnostic company
displayed DxI 9000 Access Immunoassay Analyzer on May 15, 2023, which is the
most productive immunoassay analyzer till date. DxI 9000 Access Immunoassay Analyzer has received its
approval from United States Food and Drug Administration (FDA) and CE mark under
the In Vitro Diagnostic Regulation (IVDR) which makes it accessible among
countries in Asia Pacific (APAC), Eastern Europe, the Middle East, and Africa
(EEMEA), and Latin America regions. The analyzer is advanced in measuring
concentrations of N-terminal pro B-type natriuretic peptide which gets produced
in the person’s heart and provide results within 11 minutes of the test. The DxI 9000 Access Immunoassay Analyzer utilizes chemiluminescent
technology for the detection of analytes in patient samples such as tumor
markers (PSA, CA-125), infectious disease markers (HIV, hepatitis), cardiac
markers (troponin, B-type natriuretic peptide), and hormones (thyroid-stimulating
hormone, insulin).
The DxI
9000 Access Immunoassay Analyzer has emerged as a successful solution in
addressing the demands of speed, quality, reliability, and reproducibility in
today’s world. ZeroDaily Maintenance has reduced the annual maintenance
routines of analyzer by up to 96% which drives the DxI 9000 Analyzer's uptime
performance. PrecisionVision Technology has assisted in improving the
reliability and accuracy of the analyzer by using automated safeguards such as
cap detection, sample aspiration, tube identification, residual wash volume,
and substrate volume. Moreover, recent development of DxS IntelliServe by Beckman
Coulter, Inc. is a premium remote service and diagnostics solution which can be
connected to DxI 9000 Access Immunoassay Analyzer for resolving issues with
real-time monitoring and report operation.
According to the President of
Beckman Coulter Diagnostics,
"The DxI 9000 Access Immunoassay Analyzer sets new expectations for
immunoassay testing operational performance and ability to develop and sustain
improved assay sensitivity to meet tomorrow's analytical needs. Those in the
laboratory will treasure ZeroDaily Maintenance to save them time,
PrecisionVision Technology to safeguard against flawed data reports, and
IntelliServe to maximize system uptime. At the same time, clinical researchers
are excited about the DxI 9000 Analyzer's capability to keep pace with
increasingly sensitive testing requirements as healthcare providers and
pharmaceutical companies take aim at ever more challenging diseases. An
inspiring feat of technology, the DxI 9000 Analyzer is a comprehensive
healthcare innovation."
According to TechSci Research, Adoption of novel
strategies and new product launches have always emerged as prominent ways to
achieve technological advances in the global healthcare system. Several leading
companies based in the developing countries of the world such as United States
of America, Germany, Japan, Switzerland, China, and South Korea are actively
involved in developing and commercializing advanced immunoassay analyzer
systems. However, The DxI 9000 Access Immunoassay
Analyzer, launched by US company Beckman Coulter, Inc., has emerged as a
compelling solution to bring new operational performance to immunoassay testing
while maintaining increased assay sensitivity to meet analytical needs Additionally,
DxI 9000 analyzer is considered as a boon to healthcare system of the world due
to its enhanced productivity by performing up to 215 tests per hour per square
meter (tests/hr/m2).